Flex Pharma, Inc. — 2014 Form 10-K summary
Entity note: The filing is for Flex Pharma, Inc., not Decoy Therapeutics Inc. It reports the fiscal year ended December 31, 2014, but the company was incorporated on February 26, 2014; financial results therefore cover inception through year-end, not a full year. The filing also provides unaudited quarterly results, including Q4 2014.
Business context and reporting period
Flex Pharma was an early-stage biotechnology company developing products intended to reduce muscle cramps and spasms through activation of TRP sensory-neuron channels. Its planned drug focus was nocturnal leg cramps and severe neuromuscular conditions; it was also developing a dietary-supplement consumer product for exercise-associated cramps. At year-end, drug candidates remained preclinical. The company had no approved products and had generated no revenue.
Financial results and liquidity
| Metric | Inception to December 31, 2014 |
|---|---|
| Revenue | $0 |
| Research and development expense | $4.0 million |
| General and administrative expense | $4.0 million |
| Operating loss | $8.0 million |
| Interest income | $18,946 |
| Net loss | $8.0 million; basic and diluted loss per share of $4.57 |
| Cash and working capital at year-end | $33.9 million cash; $33.2 million working capital |
| Total assets / total liabilities | $35.6 million / $1.1 million |
| Debt | No long-term debt reported |
| Operating cash flow | $(6.5) million |
There is no full-year prior-period comparison because the company began operations in 2014. In Q4 2014, operating expenses were $3.75 million and net loss was $3.74 million, versus operating expenses of $1.99 million and net loss of $1.99 million in Q3. No revenue or margin was reported.
After year-end, the February 2015 IPO raised approximately $79.9 million net. Management estimated that year-end cash together with IPO proceeds would fund its operating plan through mid-2018, while warning that actual cash needs could be higher. The company reported $824,173 in operating-lease commitments at year-end and no material off-balance-sheet arrangements.
Material changes and outlook
- Flex completed three small, randomized, blinded, placebo-controlled crossover studies in 37 healthy volunteers during 2014. The company reported statistically significant reductions in electrically induced cramp intensity in each study; no serious adverse events were reported. The filing cautions that small samples limit reliability and generalizability.
- The first proof-of-concept study in people with frequent nocturnal leg cramps was planned under the dietary-supplement framework, with treatment completion anticipated in Q2 2015 and study completion estimated at 12–15 months. These studies were not drug trials conducted under an IND.
- The consumer product was in formulation and launch preparation, with launch targeted for the first half of 2016. The drug candidates required further candidate selection, preclinical testing, an IND and subsequent clinical development; a Phase 2 trial was conditional on favorable proof-of-concept results.
- Management expected operating losses and negative cash flows for the foreseeable future and anticipated needing additional funding to develop drug candidates and commercialize products. Future financing could dilute shareholders or require licensing or partnership arrangements.
Risks, contingencies and unusual items
- Development and regulatory risk is substantial: no drug candidate had entered drug clinical trials, and dietary-supplement study results may not establish efficacy or support the drug-development plan.
- The active ingredients include capsaicin, which can cause irritation and burning; future trials or marketed products could reveal adverse effects. The company also noted that 49% of subjects in its completed studies had inconclusive results or did not show reduced electrically induced cramps.
- The consumer product’s regulatory status and permitted claims are uncertain; FDA or FTC action could require changes, restrict marketing, or result in withdrawal or recall.
- Flex relied on third parties for research, clinical work, manufacturing and future distribution, with no long-term supply commitments at year-end. It had no established sales or marketing capability.
- Intellectual-property protection was limited to pending patent applications, provisionals, trade secrets and know-how; the filing notes that the active ingredients themselves were not patentable compositions of matter.
- A perpetual 2% aggregate royalty on gross sales of qualifying neuromuscular products was payable to founders. The filing reported no royalty due at year-end.
- The company reported no material litigation. Disclosure controls were assessed as effective; management did not provide an internal-control effectiveness report, citing the newly public company transition period.
Important facts for investors to verify
- Confirm the issuer identity: this filing is Flex Pharma, Inc., whereas the request names Decoy Therapeutics Inc.
- Review the audited financial statements and notes, especially cash, operating cash use, stock-based compensation and post-IPO proceeds.
- Track whether the nocturnal-leg-cramp proof-of-concept study enrolled and completed as planned, and assess its results separately from the small healthy-volunteer studies.
- Verify progress toward an IND, preclinical safety work and a drug candidate with demonstrated activity; these were not completed at year-end.
- Monitor actual cash burn against the mid-2018 runway estimate, future financing and dilution, and the consumer product’s launch, regulatory compliance and commercial uptake.